

Special Issue

Psychiatry: Biomarkers, Genetics and Treatment Strategies

Message from the Guest Editors

Currently, recent advances in genetics and genomics provide insights into the genetic basis of psychiatry. Understanding fundamental regulatory mechanisms such as signaling pathways, high-dimensional chromatin structure, epigenetic modifications, and transcription factors has become critical for identifying new therapeutic targets in psychiatry. Furthermore, a deeper understanding of how these regulatory processes affect gene expression could provide new avenues for the development of targeted treatments for psychiatric disorders. Therefore, a better understanding of genomic regulation and mechanisms in psychiatry has become crucial for psychiatric prediction, diagnosis, and treatment. Additionally, the combination of biomarkers with computational psychiatry and machine learning for predictive analytics will be a key factor driving the field forward. So if future research is promising to develop potential biomarkers of psychiatric disorders to help determine the prediction, diagnosis, and staging of psychiatric disorders, it is also crucial for every patient suffering from psychiatric disorders.

Guest Editors

Prof. Dr. Anamaria Ciubara

Clinical-Medical Department, Faculty of Medicine and Pharmacy, "Dunărea de Jos" University of Galati, 800201 Galati, Romania

Prof. Dr. Michael Davidson

University of Nicosia Medical School, Nicosia, Cyprus

Deadline for manuscript submissions

closed (5 February 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/181077

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).